MARKET

NBRV

NBRV

Nabriva Therapeutics Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1932
-0.0068
-3.40%
Closed 19:59 05/20 EDT
OPEN
0.2151
PREV CLOSE
0.2000
HIGH
0.2151
LOW
0.1900
VOLUME
774.90K
TURNOVER
--
52 WEEK HIGH
2.320
52 WEEK LOW
0.1900
MARKET CAP
12.21M
P/E (TTM)
-0.2063
1D
5D
1M
3M
1Y
5Y
BRIEF-Nabriva Therapeutics Reports First Quarter 2022 Financial Results
reuters.com · 05/05 22:18
Nabriva Therapeutics Q1 EPS $(0.20) Misses $(0.19) Estimate, Sales $8.00M Miss $9.57M Estimate
Nabriva Therapeutics (NASDAQ:NBRV) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 62.26 percent increase over losses of $(0.53) per share
Benzinga · 05/05 20:52
Nabriva Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $8.02M misses by $1.55M
Nabriva Therapeutics press release (NASDAQ:NBRV): Q1 GAAP EPS of -$0.20 misses by $0.01. Revenue of $8.02M (+218.3% Y/Y) misses by $1.55M.
Seekingalpha · 05/05 20:33
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- -Phase 1 XENLETA Cystic Fibrosis Trial Enrollment Progressing- -Conference Call Today at 4:30 p.m. Eas...
GlobeNewswire · 05/05 20:01
-- Earnings Flash (NBRV) NABRIVA THERAPEUTICS US Posts Q1 Loss $-0.20, vs. Street Est of $-0.19
MT Newswires · 05/05 16:36
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
Nabriva extends exclusive contract to sell Merck's antibacterial drug Sivextro in US
Ireland's Nabriva Therapeutics (NASDAQ:NBRV) said it extend its exclusive agreement with Merck (MRK) to promote and distribute the Kenilworth, N.J.-based company's antibacterial drug Sivextro in the U.S. till Dec. 31, 2026. Sivextro
Seekingalpha · 05/05 12:23
BRIEF-Nabriva Extends Exclusive Agreement To Promote And Distribute Sivextro (Tedizolid Phosphate) In The U.S. Through The End Of 2026
reuters.com · 05/05 12:22
More
No Data
Learn about the latest financial forecast of NBRV. Analyze the recent business situations of Nabriva Therapeutics Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
50.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NBRV stock price target is 1.675 with a high estimate of 2.000 and a low estimate of 1.350.
High2.000
Average1.675
Low1.350
Current 0.1932
EPS
Actual
Estimate
-0.28-0.21-0.14-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 78
Institutional Holdings: 13.38M
% Owned: 21.17%
Shares Outstanding: 63.20M
TypeInstitutionsShares
Increased
4
116.65K
New
7
494.21K
Decreased
7
582.63K
Sold Out
12
1.04M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director/Supervisory Board
Daniel Burgess
President/Chief Operating Officer/Director
Steven Gelone
Chief Executive Officer/Director
Theodore Schroeder
Chief Financial Officer
Daniel Dolan
General Counsel/Secretary
Robert Crotty
Other
Christine Guico-pabia
Director
Colin Broom
Independent Director/Supervisory Board
Carrie Bourdow
Independent Director/Supervisory Board
Mark Corrigan
Independent Director/Supervisory Board
Lisa Dalton
Independent Director/Supervisory Board
Charles Rowland
Independent Director/Supervisory Board
Stephen Webster
No Data
No Data
About NBRV
Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Webull offers kinds of Nabriva Therapeutics PLC - ADR stock information, including NASDAQ:NBRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBRV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBRV stock methods without spending real money on the virtual paper trading platform.